Outcomes of cataract surgery in diabetic patients: results of the PanAmerican Collaborative Retina Study Group

Show simple item record

dc.contributor.author Gallego-Pinazo, Roberto
dc.contributor.author Dolz-Marco, Rosa
dc.contributor.author Berrocal, Maria
dc.contributor.author Wu, Lihteh
dc.contributor.author Maia, Maurício [UNIFESP]
dc.contributor.author Serrano, Martín
dc.contributor.author Alezzandrini, Arturo
dc.contributor.author Arévalo, J. Fernando
dc.contributor.author Díaz-Llopis, Manuel
dc.date.accessioned 2015-06-14T13:47:24Z
dc.date.available 2015-06-14T13:47:24Z
dc.date.issued 2014-12-01
dc.identifier http://dx.doi.org/10.5935/0004-2749.20140089
dc.identifier.citation Arquivos Brasileiros de Oftalmologia. Conselho Brasileiro de Oftalmologia, v. 77, n. 6, p. 355-359, 2014.
dc.identifier.issn 0004-2749
dc.identifier.issn 1678-2925
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/8690
dc.description.abstract Purpose:This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies.Methods:The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3).Results:The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 µm (± 35.7) at baseline to 274.57 µm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 µm (± 100.4) to 339.56 µm (± 145.3) (p=0.184) in Group 2; and from 259.18 µm (± 97.9) to 282.21 µm (± 87.24) (p=0.044) in Group 3.Conclusion:Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy. en
dc.description.abstract Objetivo:Avaliar os resultados visuais e anatômicos após a cirurgia de catarata em pacientes diabéticos com estratégias terapêuticas intraoperatórias diferentes.Métodos:Estudo multicêntrico, retrospectivo, de intervenção realizado em 6 centros da Argentina, Brasil, Costa Rica, Porto Rico, Espanha e Venezuela. Foram incluído 138 pacientes diabéticos com pelo menos 6 meses de seguimento apó facoemulsificação com implante de lente intraocular. Acuidade visual melhor corrigida (BCVA) e a espessura subcampo central (CST ) foram coletadas no início e em 1, 2, 3 e 6 meses de seguimento. Destes, 42 casos não foram tratadas com qualquer co-adjuvante de medicamentos intra-operatório (Grupo 1), 59 paciente receberam bevacizumab intraoperatório (Grupo 2), e 37 pacientes receberam triancinolona intraoperatória (4 mg/0,1 ml) (Grupo 3).Resultados:A média logMAR (± desvio-padrão [DP]) BCVA melhorou de 0,82 (± 0,43) no início do estudo, para 0,14 (± 0,23) aos 6 meses de seguimento (p<0,001) no Grupo 1; de 0,80 (± 0,48) para 0,54 (± 0,45) (p<0,001) no Grupo 2; e de 1,0 (± 0,40) para 0,46 (± 0,34) (p<0,001) no Grupo 3. A CST média aumentou de 263,57 µm (± 35,7) na linha de base para 274,57±48,7 µm em 6 meses acompanhamento (p=0,088) no Grupo 1; de 316,02 µm (± 100,4), para 339,56 µm (± 145,3) (p=0,184) no Grupo 2; e de 259,18 µm (± 97,9), para 282,21 µm (±87,24) (p=0,044) no grupo 3.Conclusões:Pacientes diabéticos podem se beneficiar significativamente da cirurgia de catarata. Este estudo parece fornecer evidências para apoiar o uso de triancinolona intravítrea ou bevacizumab no momento da cirurgia de catarata em casos com edema macular diabético preexistente (DME) ou retinopatia diabética não-proliferativa moderada a grave. pt
dc.format.extent 355-359
dc.language.iso eng
dc.publisher Conselho Brasileiro de Oftalmologia
dc.relation.ispartof Arquivos Brasileiros de Oftalmologia
dc.rights Acesso aberto
dc.subject Diabetic retinopathy en
dc.subject Macular edema en
dc.subject Cataract extraction en
dc.subject Intraoperative care en
dc.subject Phacoemulsification en
dc.subject Lens implantation, intraocular en
dc.subject Antibodies, monoclonal en
dc.subject Multicenter study en
dc.subject Retinopatia diabética pt
dc.subject Edema macular pt
dc.subject Extração de catarata pt
dc.subject Cuidados intraoperatórios pt
dc.subject Facoemulsificação pt
dc.subject Implante de lente intraocular pt
dc.subject Anticorpos monoclonais pt
dc.subject Estudo multicêntrico pt
dc.title Outcomes of cataract surgery in diabetic patients: results of the PanAmerican Collaborative Retina Study Group en
dc.title.alternative Resultados da cirurgia de catarata em pacientes diabéticos: resultado do Pan-American Collaborative Retina Study Group pt
dc.type Artigo
dc.contributor.institution University and Polytechnic Hospital La Fe Department of Ophthalmology
dc.contributor.institution University of Puerto Rico Department of Ophthalmology
dc.contributor.institution Instituto de Cirugía Ocular
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Clinica Oftalmologica Centro Caracas
dc.contributor.institution Arevalo-Coutinho Foundation for Research in Ophthalmology
dc.contributor.institution Universidad de Buenos Aires Cátedra de Oftalmologia
dc.contributor.institution The King Khaled Eye Specialist Hospital Vitreoretinal Division
dc.contributor.institution Johns Hopkins University The Wilmer Eye Institute Retina Division
dc.contributor.institution University of Valencia Faculty of Medicine
dc.description.affiliation University and Polytechnic Hospital La Fe Department of Ophthalmology
dc.description.affiliation University of Puerto Rico Department of Ophthalmology
dc.description.affiliation Instituto de Cirugía Ocular
dc.description.affiliation Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Department of Ophthalmology and Visual Sciences
dc.description.affiliation Clinica Oftalmologica Centro Caracas
dc.description.affiliation Arevalo-Coutinho Foundation for Research in Ophthalmology
dc.description.affiliation Universidad de Buenos Aires Cátedra de Oftalmologia
dc.description.affiliation The King Khaled Eye Specialist Hospital Vitreoretinal Division
dc.description.affiliation Johns Hopkins University The Wilmer Eye Institute Retina Division
dc.description.affiliation University of Valencia Faculty of Medicine
dc.description.affiliationUnifesp UNIFESP, EPM, Department of Ophthalmology and Visual Sciences
dc.identifier.file S0004-27492014000600355.pdf
dc.identifier.scielo S0004-27492014000600355
dc.identifier.doi 10.5935/0004-2749.20140089
dc.description.source SciELO
dc.identifier.wos WOS:000348589700004



File

Name: S0004-27492014000600355.pdf
Size: 336.3Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account